Workflow
卫光生物(002880) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥179,587,222.01, a decrease of 36.08% compared to the same period last year[7] - The net profit attributable to shareholders for Q3 2022 was ¥25,883,259.59, down 61.77% year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥24,407,396.29, reflecting a 62.79% decrease compared to the previous year[7] - Total operating revenue for the third quarter was CNY 411,433,957.15, a decrease of 33.3% compared to CNY 616,756,759.63 in the same period last year[26] - Net profit for the third quarter was CNY 72,732,672.12, a decline of 47.0% compared to CNY 137,229,657.84 in the previous year[28] - Earnings per share for the third quarter were CNY 0.3209, down from CNY 0.6070 in the same quarter last year[28] Cash Flow and Liquidity - The operating cash flow for the year-to-date period was -¥51,123,244.76, a decline of 142.49% year-on-year[7] - Operating cash inflow for the current period was CNY 514,872,246.56, a decrease of 21.1% from CNY 652,908,945.47 in the previous period[32] - Net cash flow from operating activities was CNY -51,123,244.76, compared to CNY 120,331,844.55 in the previous period[32] - Cash and cash equivalents at the end of the period amounted to CNY 477,262,302.52, up from CNY 280,008,234.42 in the previous period[35] - The company’s cash flow from operating activities showed a significant decline, indicating potential challenges in revenue generation[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,458,912,882.11, an increase of 22.73% from the end of the previous year[7] - Total liabilities rose to CNY 639,765,748.40, compared to CNY 215,230,209.78 in the previous year[25] - The total equity attributable to shareholders of the parent company was CNY 1,796,135,412.71, up from CNY 1,768,725,498.43 in the previous year[25] Inventory and Borrowings - The company's inventory increased by 47.23% compared to the end of the previous year, attributed to higher raw material levels[11] - The company experienced a 300% increase in short-term borrowings compared to the end of the previous year, primarily due to operational needs[11] Government Support and Non-Operating Income - The company received government subsidies amounting to ¥1,939,197.97 during the reporting period, contributing to an increase in non-operating income[8] Research and Development - Research and development expenses for the third quarter were CNY 28,275,340.82, down from CNY 34,650,925.82 year-over-year[26] Future Plans and Strategies - The company is actively pursuing new product development and market expansion strategies, although specific details are not provided in the current report[18] - The company has disclosed its intention to issue new shares, which is currently under review by the China Securities Regulatory Commission[16] Employee Engagement - The company has implemented an employee stock ownership plan, which is set to expire soon, indicating a focus on employee engagement and retention[19]